

National Department of Health. (2015). *National Health Insurance for South Africa White Paper 40 – Towards universal health coverage*. Pretoria:

Available: <http://www.gpwonline.co.za>

[Downloaded: 01.2.16]

Navsa, D.M. (2003). Organising and evaluating diabetic care in general practice. *Continuing Medical Education*, 21 (10):599-604.

NCSS 9 Statistical Software. (2013). NCSS, LLC. Kaysville, Utah, USA.

Available: <http://www.ncss.com/software/ncss>

[Downloaded: 01.2.16]

Pizzarello, L., Abiose, A., Ffytche, T., Duerksen, R., Thulasiraj, R., Tay-

lor, H., Faal, H., Rao, G., Kocur, I. and Resnikoff, S. (2004). Vision

2020: The Right to Sight. A Global Initiative to Eliminate Avoidable

Blindness. *Archives of Ophthalmology*, 122: 615-620.

Read, O. and Cook, C. (2007). Retinopathy in diabetic patients evaluated at a primary care clinic in Cape Town. *South African Medical Journal*, 97(10): 941-945.

Rispel, L., Moorman, J., Chersich, M., Goudge, J., Nxumalo, N., *et al.* (2010). *Re-vitalising primary health care in South Africa: Review of primary health care package, norms and standards*. Johannesburg: Centre for Health Policy, University of Witwatersrand.

Sambo, B.M. (2007). The diabetes strategy for the WHO African Region: a call to action. Diabetes in society. *Diabetes Voice*, 52 (4):35-37.

Sattar, N., Sorensen, T., Taylor, A.E., Morris, R. and Munafo, M.R. (2015). Smoking and diabetes risk: building a causal case with clinical implications. *The Lancet: Diabetes and Endocrinology*, 24 (10):918-919.

Statistics South Africa. (2013). *City of Cape Town: Census 2011*. Pretoria.

Stefánsson, E., Bek, T., Porta, M., Larsen, N., Kristinsson, J.K., and Agardh, E. (2000). Screening and prevention of diabetic blindness. *Acta Ophthalmologica*, 78:374-385.


Spijkerman, A.M.W., Dekker, J.M., Nijpels, G., Adriaanse, M.C., Kostense, P.J., Ruwaard, D., Stehouwer, C.D.A., Bouter, L.M. and Heine, R.J. (2003). Microvascular complications at time of diagnosis of Type 2 Diabetes are similar among diabetic patients detected by targeted screening and patients newly diagnosed in general practice. *Diabetes Care*, (26): 2604-2608.

United Nations. (2015). *Transforming our world: The 2030 agenda for sustainable development*. New York City.

Van Leiden, H.A., Dekker, J.M., Moll, A.C., Nijpels, G., Heine, R.J., Bouter, L.M., Stehouwer, C.D.A. and Polak, B.C.P. (2003). The Hoorn Study. Risk factors for incident retinopathy in a diabetic and nondiabetic population. *Archives of Ophthalmology*, (121): 245– 251.

World Health Organization. (2016). *Global report on diabetes*. Geneva.

Wild, S., Roglic, G., Green, A., Sicree, R. and King, H. (2004). Global Prevalence of Diabetes. Estimates of for the year 2000 and projections for 2030. *Diabetes Care*, 27:1047-53.



APPENDICES

INFORMATION SHEET

Project Title: Factors associated with diabetic retinopathy requiring treatment on fundal photography in participants of the Cape Town Diabetic Retinopathy Screening programme.

What is this study about?

This is a research project being conducted by Mr HG Alexander at the University of the Western Cape. We are inviting you to participate in this research project because you are diabetic patient receiving medical care at a community health centre within the circumscribed study area. The purpose of this research project is to ascertain if there is any notable differences amongst the characteristic of a diabetic patient who presents with treatment-requiring diabetic retinopathy and those who present with non-treatment-requiring diabetic retinopathy.

What will I be asked to do if I agree to participate?

You will be asked to undergo retinal camera imaging which will coincide with your diabetic visit at your attending clinic. Thereafter an interviewer will ask you some general information with regards to your overall health and well-being. The other relevant study information will be sourced from your clinical folder.

Would my participation in this study be kept confidential?

We will do our best to keep your personal information confidential. To help protect your confidentiality, a code will be assigned to each patient thus keeping your particulars confidential. The review of the folders will be conducted on-site with permission from the relevant facility manager.

What are the risks of this research?

There are no risks associated with participating in this research project beyond the usual care you receive at the clinic.

What are the benefits of this research?

The benefits to you is to have the back of your eye photographed and evaluated by a professional grader, and include the necessary follow up care. The study forms part of the

current diabetic retinal screening program conducted at your facility, and the information obtained will lead to future improvements.

Do I have to be in this research and may I stop participating at any time?

Your participation in this research is completely voluntary. You may choose not to take part at all. If you decide to participate in this research, you may stop participating at any time. If you decide not to participate in this study or if you stop participating at any time, you will not be penalized or lose any benefits to which you otherwise qualify

Is any assistance available if I am negatively affected by participating in this study?

If you feel that partaking in the study had a negative impact either socially, emotionally and/or physically then assistance will be provided from the relevant facility managers.

What if I have questions?

This research is being conducted by Mr HG Alexander from the University of the Western Cape. If you have any questions about the research study itself, please contact myself at:

The Woodstock Hospital (Eye Clinic)

Mountain Road

Woodstock

7925

Tel: (021) 447 0007

Email: henry.george.alexander@gmail.com

Should you have any questions regarding this study and your rights as a research participant or if you wish to report any problems you have experienced related to the study, please contact:

Director:

Prof Helene Schneider

School of Public Health

University of the Western Cape

Private Bag X17

Bellville 7535

hschneider@uwc.ac.za

Dean of the Faculty of Community and Health Sciences:

Prof Jose Frantz

University of the Western Cape

Private Bag X17

Bellville 7535

chs-deansoffice@uwc.ac.za





OFFICE OF THE DEAN
DEPARTMENT OF RESEARCH DEVELOPMENT

08 June 2015

To Whom It May Concern

I hereby certify that the Senate Research Committee of the University of the Western Cape approved the methodology and ethics of the following research project by:

Mr HG Alexander (School of Public Health)

Research Project:



UNIVERSITY of the
WESTERN CAPE

Factors associated with diabetic retinopathy requiring treatment based on fundal photography in participants of the Cape Town Retinal Screening Programme.

Registration no:

15/4/35

Any amendments, extension or other modifications to the protocol must be submitted to the Ethics Committee for approval.

The Committee must be informed of any serious adverse event and/or termination of the study.

A handwritten signature in black ink, appearing to read 'Patricia Josias', is located below the text.

Ms Patricia Josias
Research Ethics Committee Office
University of the Western Cape

FIRST NAME	SURNAME	GENDER
ID	AGE	CHC
TEL NO	ADDRESS	

Place Clinic Sticker here

OCULAR HISTORY		DIABETES TYPE OF TREATMENT	DIAB ETE
CO-MORBIDITIES		ORAL SUPPLEMENTS	
SMOKING NO YESNUMBER OF PACKS PER DAY			
ALCOHOL CONSUMPTION DRINKS PER WEEK			
DATE OF LAST FUNDUS PHOTOGRAPH		DRS ATTENDANCE HISTORY IN THE PAST FIVE YEARS	

CLINICAL MEASUREMENT			CLINICIAN:
HEIGHT	WIEGHT	BP	WASIT CIRCUMFERENCE
BLOOD GLUCOSE	TODAY	6 MONTH AVERAGE	ONE YEAR AGO
MOST RECENT HBA1C		PEDAL EXAM	

EYE EXAMINATION		CLINICIAN:
HABITUAL VISUAL ACUITY	R	L
PINHOLE VISUAL ACUITY	R	L
INTRA OCULAR PRESSURE	R	L
RED REFLEX PRESENT	R	L
PUPIL REFLEX	R	L

DIABETIC RETINOPATHY SCREEN- ING	RIGH T EYE	LEFT EYE GRAD	FOLLOW UP CARE
NO DIABETIC RETINOPATHY			ANNUAL REVIEW
MILD/ MODERATE DIABETIC RETINOPATHY			6 MONTHS REVIEW
SEVERE DIABETIC RETINOPATHY			REFER TO OPTOMETRIST
PROLIFERATIVE DIABETIC RETINOPAHTY			REFER FOR TREATMENT
MACULAR INVOLVEMENT			

I HEREBY DECLARE THAT THE NATURE OF THE STUDY WAS CLEARLY EXPLAINED TO ME, AND THAT I CONSENT TO PARTAKING IN THIS STUDY.